½ÃÀ庸°í¼­
»óǰÄÚµå
1586131

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå : À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Cardiovascular Implants Market by Type (Cardiac Resynchronization Therapy Device, Coronary Stents, Heart Valves), End-User (Cardiac Care Centers, Hospitals, Specialty Clinics) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀº 2023³â¿¡ 332¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 353¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.21%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 507¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå¿¡´Â ¼Õ»óµÈ ½ÉÀå Á¶Á÷°ú Ç÷°üÀ» º¹±¸Çϰųª ±³Ã¼ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±â°¡ Æ÷ÇԵǸç, ½ºÅÙÆ®, ½É¹ÚÁ¶À²±â, Á¦¼¼µ¿±â, ½ÉÀåÆÇ¸·, ½É½Çº¸Á¶ÀåÄ¡(VAD) µîÀÌ ±¤¹üÀ§ÇÏ°Ô Æ÷ÇԵ˴ϴÙ. °í·ÉÈ­, ÁÂ½Ä »ýȰ½À°ü, ºñ¸¸ Áõ°¡·Î ÀÎÇÑ ½ÉÇ÷°ü°è Áúȯ(CVDs) Áõ°¡·Î ÀÎÇØ ±× Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½É¹ÚÁ¶À²±â¸¦ ÅëÇÑ ºÎÁ¤¸Æ Ä¡·á, ½ºÅÙÆ®¸¦ ÅëÇÑ µ¿¸Æ ¸·Èû Á¦°Å, º¸Á¶±â±¸¸¦ ÅëÇÑ ½ÉÀå ±â´É Áö¿ø µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ¸ç, ÁÖ·Î º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ½ÉÀå Ä¡·á ¼¾ÅÍ¿¡¼­ »ç¿ëµË´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ÃÖ¼Òħ½ÀÀû ½Ã¼úÀ» ÃËÁøÇÏ´Â ±â¼ú ¹ßÀü, ÀÇ·áºñ ÁöÃâ ±ÞÁõ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ È¯ÀÚ ÀÎ½Ä Çâ»ó°ú ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î ÀÎÇÑ °ßÁ¶ÇÑ ¼ö¿ä¸¦ ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ »ýü ÀûÇÕ¼º Àç·áÀÇ Çõ½Å, AI¸¦ Ȱ¿ëÇÑ Áø´Ü, Á¤È®µµ¸¦ ³ôÀ̰í ȸº¹ ½Ã°£À» ´ÜÃàÇÏ´Â ·Îº¿ º¸Á¶ ¼ö¼úÀÇ °³¼± µî ºñÁî´Ï½º ±âȸ´Â dzºÎÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº ¼ö¼ú ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦, ÀáÀçÀûÀÎ ±â±â °áÇÔ µîÀÇ Á¦¾àÀÌ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­ÀÇ Á¦ÇÑÀûÀÎ º¸Çè±Þ¿©¿Í ±ä ½ÂÀÎ ÀýÂ÷ µîÀÇ ¹®Á¦´Â »óȲÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ±â¾÷µéÀº »ýºÐÇØ¼º ½ºÅÙÆ® ¹× Â÷¼¼´ë Á¦¼¼µ¿±â ¿¬±¸°³¹ß¿¡ ÁýÁßÇÔÀ¸·Î½á ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á Æ®·»µå Áõ°¡´Â ½ÉÇ÷°ü ÀÓÇöõÆ®¿Í ÅëÇÕµÈ ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ °¡´É¼ºÀ» ½Ã»çÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Áö¼ÓÀûÀΠȯÀÚ °ü¸® ¹× µ¥ÀÌÅÍ ¼öÁýÀ» À§ÇÑ »õ·Î¿î Æ®·»µå¸¦ ¿­¾îÁÙ °ÍÀÔ´Ï´Ù. ½ÃÀå °æÀïÀº ¿©ÀüÈ÷ Ä¡¿­Çϸç, ±â¾÷µéÀº Àü·«Àû Á¦ÈÞ¿Í ÇÕº´À» ÅëÇØ ±â¼ú·ÂÀ» °­È­Çϰí Áö¸®Àû ¹üÀ§¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ½ÃÀåÀÇ ÀáÀç·ÂÀ» ÃÖ´ëÇÑ È°¿ëÇϱâ À§ÇØ ÁøÈ­Çϴ ȯÀÚÀÇ ¿ä±¸, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, °æÀï ±¸µµ¿¡ Ç×»ó ÁÖÀǸ¦ ±â¿ï¿©¾ß ÇÕ´Ï´Ù. ±â¼ú Çõ½ÅÀº ±â±âÀÇ ¼ö¸íÀ» ¿¬ÀåÇϰí ħ½À¼ºÀ» ÁÙ¿© ȯÀÚ °á°ú¿Í ºñ¿ë È¿À²¼ºÀ» °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 332¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 353¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 507¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 6.21%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ½ÉÇ÷°ü°è Áúȯ Áõ°¡
    • Á¤ºÎ±â°üÀÇ ¿ìÈ£ÀûÀÎ »óȯ Á¤Ã¥
    • ½ÉÇ÷°ü ÀÓÇöõÆ®ÀÇ È¿°ú ¹× ¾ÈÀü¼º Çâ»ó
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾ö°ÝÇÑ ½ÂÀÎ ÇÁ·Î¼¼½º¿Í ³ôÀº ÀåÄ¡ ºñ¿ë
  • ½ÃÀå ±âȸ
    • ÀÓÇöõÆ® 3D ÇÁ¸°ÆÃ ¹× ÀÇ·á¿ë ¹ÙÀÌ¿À Æú¸®¸Ó ¹× ¹ÙÀÌ¿À ¼ÒÀç °³¹ß
    • ½º¸¶Æ® ½ÉÇ÷°ü ÀÓÇöõÆ® °³¹ß
  • ½ÃÀå °úÁ¦
    • º¹ÀâÇÑ ÀÓÇöõÆ® ¼³°è, »ýü ±â´ÉÈ­ ¹× °øÁ¤ °³¹ß

Portre's Five Forces ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå : À¯Çüº°

  • ½ÉÀå À絿±âÈ­ ¿ä¹ý Àåºñ
  • °ü»óµ¿¸Æ ½ºÅÙÆ®
  • ½ÉÀåÆÇ¸·
  • »ðÀÔÇü Á¦¼¼µ¿±â
  • ¸Å¸³Çü ½ÉÀå ÆäÀ̽º¸ÞÀÌÄ¿
  • ¸»ÃÊ ½ºÅÙÆ®

Á¦7Àå ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÉÀå ÄÉ¾î ¼¾ÅÍ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÉÇ÷°ü ÀÓÇöõÆ® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Artivion, Inc.
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardiac Implants, LLC
  • Edwards Lifesciences Corporation
  • Johnson & Johnson Services, Inc.
  • LivaNova PLC
  • Medtronic PLC
  • Neovasc Inc.
  • Sorin Corporation
  • Terumo Corporation
LSH.

The Cardiovascular Implants Market was valued at USD 33.26 billion in 2023, expected to reach USD 35.30 billion in 2024, and is projected to grow at a CAGR of 6.21%, to USD 50.72 billion by 2030.

The cardiovascular implants market encompasses medical devices used to repair or replace damaged heart tissues and vessels, broadly including stents, pacemakers, defibrillators, heart valves, and ventricular assist devices. Their necessity is driven by rising incidences of cardiovascular diseases (CVDs), often attributed to aging populations, sedentary lifestyles, and increasing prevalence of obesity. Applications range from treating arrhythmias with pacemakers, unclogging blocked arteries with stents, to supporting heart function via assist devices, primarily used in hospitals, ambulatory surgical centers, and cardiac care centers. Key growth influencers include technological advancements fostering minimally invasive procedures, a surge in healthcare expenditure, and robust demand bolstered by escalating patient awareness and improving healthcare infrastructure in emerging markets. Notably, opportunities abound in the innovation of biocompatible materials, AI-driven diagnostics, and improvements in robotic-assisted surgeries to enhance precision and reduce recovery times. However, limitations such as high procedure costs, stringent regulatory landscapes, and potential device malfunctions pose significant challenges. Issues like limited reimbursement in developing regions and lengthy approval processes further complicate the scenario. Despite these barriers, businesses can concentrate on research and development in biodegradable stents and next-generation defibrillators to fortify market position. The growing telemedicine trend also suggests potential for remote monitoring solutions integrated with cardiovascular implants, opening avenues for continuous patient care and data collection. Market nature remains competitive with players focusing on strategic collaborations, mergers to capitalize on technological prowess, and expand geographic reach. Companies should stay attuned to evolving patient needs, regulatory frameworks, and competitive actions in order to harness full market potential. Innovation should lean towards enhancing device longevity and reducing invasive nature, thereby improving patient outcomes and cost-efficacy.

KEY MARKET STATISTICS
Base Year [2023] USD 33.26 billion
Estimated Year [2024] USD 35.30 billion
Forecast Year [2030] USD 50.72 billion
CAGR (%) 6.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiovascular Implants Market

The Cardiovascular Implants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing health consciousness and growing occurrences of cardiovascular disorders
    • Favorable reimbursement policies by government agencies
    • Improved efficacy and safety of cardiovascular implants
  • Market Restraints
    • Strict approval process and high cost of devices
  • Market Opportunities
    • 3D printing of implants and development of medical Biopolymers and biomaterials
    • Development of smart cardiovascular implants
  • Market Challenges
    • Complicated implant design, biofunctionalization, and process development

Porter's Five Forces: A Strategic Tool for Navigating the Cardiovascular Implants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiovascular Implants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiovascular Implants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiovascular Implants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiovascular Implants Market

A detailed market share analysis in the Cardiovascular Implants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiovascular Implants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiovascular Implants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiovascular Implants Market

A strategic analysis of the Cardiovascular Implants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Implants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Artivion, Inc., B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardiac Implants, LLC, Edwards Lifesciences Corporation, Johnson & Johnson Services, Inc., LivaNova PLC, Medtronic PLC, Neovasc Inc., Sorin Corporation, and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Implants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cardiac Resynchronization Therapy Device, Coronary Stents, Heart Valves, Implantable Cardioverter Defibrillator, Implanted Cardiac Pacemakers, and Peripheral Stents.
  • Based on End-User, market is studied across Cardiac Care Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing health consciousness and growing occurrences of cardiovascular disorders
      • 5.1.1.2. Favorable reimbursement policies by government agencies
      • 5.1.1.3. Improved efficacy and safety of cardiovascular implants
    • 5.1.2. Restraints
      • 5.1.2.1. Strict approval process and high cost of devices
    • 5.1.3. Opportunities
      • 5.1.3.1. 3D printing of implants and development of medical Biopolymers and biomaterials
      • 5.1.3.2. Development of smart cardiovascular implants
    • 5.1.4. Challenges
      • 5.1.4.1. Complicated implant design, biofunctionalization, and process development
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiovascular Implants Market, by Type

  • 6.1. Introduction
  • 6.2. Cardiac Resynchronization Therapy Device
  • 6.3. Coronary Stents
  • 6.4. Heart Valves
  • 6.5. Implantable Cardioverter Defibrillator
  • 6.6. Implanted Cardiac Pacemakers
  • 6.7. Peripheral Stents

7. Cardiovascular Implants Market, by End-User

  • 7.1. Introduction
  • 7.2. Cardiac Care Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Cardiovascular Implants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cardiovascular Implants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cardiovascular Implants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Artivion, Inc.
  • 3. B. Braun Melsungen AG
  • 4. BIOTRONIK SE & Co. KG
  • 5. Boston Scientific Corporation
  • 6. Cardiac Implants, LLC
  • 7. Edwards Lifesciences Corporation
  • 8. Johnson & Johnson Services, Inc.
  • 9. LivaNova PLC
  • 10. Medtronic PLC
  • 11. Neovasc Inc.
  • 12. Sorin Corporation
  • 13. Terumo Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦